![]() |
|
|
Vol. 290, Issue 3, 1148-1156, September 1999
Drug Development Group, Behavioral Neuroscience Branch, Addiction
Research Center, National Institute on Drug Abuse, National Institutes
of Health, Baltimore, Maryland
Seizures and status epilepticus are among the neurological
complications of cocaine overdose in humans. The aim of the present study was to evaluate the protective effectiveness and therapeutic index (separation between anticonvulsive and side effect profiles) of
14 newly approved and potential antiepileptic drugs using a murine
model of acute cocaine toxicity and the inverted-screen test for
behavioral side effect testing. Cocaine (75 mg/kg i.p.) produces clonic
seizures (~90% of mice), and conventional antiepileptic drugs have
been reported to be either ineffective or only effective at doses
producing significant sedative/ataxic effects. Clobazam, flunarizine,
lamotrigine, topiramate, and zonisamide were ineffective against
seizures up to doses producing significant motor impairment. In
contrast, felbamate, gabapentin, loreclezole, losigamone, progabide, remacemide, stiripentol, tiagabine, and vigabatrin produced
dose-dependent protection against cocaine-induced convulsions with
varied separations between their anticonvulsant and side effect
profiles: the protective index values (toxic
TD50/anticonvulsive ED50) ranged from 1.26 (felbamate) to 7.67 (loreclezole), and gabapentin had the highest (protective index >152). Thus, several drugs were identified with greater protective efficacy and reduced motor impairment compared with
classic antiepileptic drugs. Based on the proposed mechanism of action
of these new anticonvulsants, it is noteworthy that 1) drugs that
enhance
-aminobutyric acid-mediated neuronal inhibition in a manner
distinct from barbiturates and benzodiazepines offer the best
protective/behavioral side effect profiles, and 2) functional antagonists of Na+ and Ca2+ channels are
generally ineffective. Overall, this study provides the first
description of the effectiveness of new antiepileptic drugs against
experimentally induced cocaine seizures and points to several drugs
that deserve clinical scrutiny for this indication.
This article has been cited by other articles:
![]() |
J. M. Witkin, D. Dijkstra, B. Levant, H. C. Akunne, A. Zapata, S. Peters, H. E. Shannon, and M. Gasior Protection against Cocaine Toxicity in Mice by the Dopamine D3/D2 Agonist R-(+)-trans-3,4a,10b-Tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907] J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 957 - 964. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Crestani, K. Löw, R. Keist, M.-J. Mandelli, H. Möhler, and U. Rudolph Molecular Targets for the Myorelaxant Action of Diazepam Mol. Pharmacol., March 1, 2001; 59(3): 442 - 445. [Abstract] [Full Text] |
||||
![]() |
M. Gasior, J. T. Ungard, and J. M. Witkin Chlormethiazole: Effectiveness against Toxic Effects of Cocaine in Mice J. Pharmacol. Exp. Ther., October 1, 2000; 295(1): 153 - 161. [Abstract] [Full Text] |
||||